ALVOTECH

NASDAQ: ALVO (Alvotech)

最近更新时间: 12 May, 9:02AM

9.68

0.30 (3.20%)

前收盘价格 9.38
收盘价格 10.12
成交量 505,913
平均成交量 (3个月) 149,645
市值 2,921,482,240
预期市盈率 (P/E Forward) 45.45
价格/销量 (P/S) 4.44
52周波幅
7.35 (-24%) — 14.65 (51%)
营业毛利率 16.42%
营业利益率 (TTM) 7.97%
稀释每股收益 (EPS TTM) 0.370
季度收入增长率 (YOY) 260.00%
季度盈利增长率 (YOY) -65.50%
流动比率 (MRQ) 1.73
营业现金流 (OCF TTM) -148.89 M
杠杆自由现金流 (LFCF TTM) -216.76 M
资产报酬率 (ROA TTM) 7.02%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看跌 混合的
Drug Manufacturers - Specialty & Generic (全球的) 混合的 混合的
股票 Alvotech 混合的 看跌

AIStockmoo 评分

-0.8
分析师共识 -2.0
内部交易活动 NA
价格波动 1.5
技术平均移动指标 0.0
技术振荡指标 -2.5
平均 -0.75

相关股票

股票 市值 DY P/E(TTM) P/B
ALVO 3 B - - -
LNTH 6 B - 23.06 4.80
KNSA 2 B - - 4.64
HROW 951 M - - 19.85
CRON 728 M - 13.50 0.680
ETON 378 M - - 15.03

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Growth
内部持股比例 63.44%
机构持股比例 6.44%

所有权

姓名 日期 持有股份
Lodbrok Capital Llp 31 Dec 2024 181,587
Oaktree Fund Advisors, Llc 31 Dec 2024 116,294

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
26 Jun 2025 公告 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
26 Jun 2025 公告 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
25 Jun 2025 公告 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25 Jun 2025 公告 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25 Jun 2025 公告 Main Results of 2025 Annual and Extraordinary General Meeting
25 Jun 2025 公告 Main Results of 2025 Annual and Extraordinary General Meeting
23 Jun 2025 公告 European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
23 Jun 2025 公告 European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
11 Jun 2025 公告 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
11 Jun 2025 公告 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
06 Jun 2025 公告 Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
06 Jun 2025 公告 Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
05 Jun 2025 公告 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
05 Jun 2025 公告 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
05 Jun 2025 公告 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
04 Jun 2025 公告 Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
04 Jun 2025 公告 Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
04 Jun 2025 公告 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
04 Jun 2025 公告 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
02 Jun 2025 公告 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
02 Jun 2025 公告 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
28 May 2025 公告 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
28 May 2025 公告 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
19 May 2025 公告 Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
19 May 2025 公告 Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today
16 May 2025 公告 Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm
09 May 2025 公告 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
09 May 2025 公告 Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada  
09 May 2025 公告 Transactions of Managers and Closely Associated Persons
08 May 2025 公告 Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
07 May 2025 公告 Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07 May 2025 公告 Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07 May 2025 公告 Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07 May 2025 公告 Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
05 May 2025 公告 Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 公告 Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
02 May 2025 公告 Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
02 May 2025 公告 Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票